Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China

Inclusion Criteria: * Patients with histologically/ cytologically documented or radiographically diagnosed unresectable HCC who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made. Radiographic diagnosis needs typical findings of HCC by radiographic method i.e. on multi-dimensional dynamic CT, CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or MRI; * Patients receive the first dose of sorafenib no later than 1 week (\<=7days) after the 3rd TACE procedure * Patients did not receive other prior systemic treatment by using target therapy * Patients must sign the informed consent form; * Patients must have a life expectancy of at least 3 months; * The physician must be willing to complete and submit all CRFs; * The physician must be willing to submit to a site audit with verification of source documents and validation of data reported; Exclusion Criteria: * The first dose of sorafenib 7 days after the 3nd TACE procedure * Exclusion criteria must follow the approved local product information